IKT
Inhibikase Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$232.38M
P/E Ratio
—
EPS
$-0.49
Beta
0.86
52W High
$2.37
52W Low
$1.33
50-Day MA
$1.78
200-Day MA
$1.70
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Inhibikase Therapeutics Inc
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside and outside the brain. The company is headquartered in Atlanta, Georgia.
Fundamentals
| Revenue (TTM) | 1 |
| Gross Profit (TTM) | $-30.63M |
| EBITDA | $-45.89M |
| Operating Margin | 0.00% |
| Return on Equity | -36.00% |
| Return on Assets | -20.50% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.02 |
| Price-to-Book | 1.38 |
| Price-to-Sales (TTM) | 10.39 |
| EV/Revenue | 0.594 |
| EV/EBITDA | 0.34 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $132.03M |
| Float | $85.42M |
| % Insiders | 6.42% |
| % Institutions | 80.20% |
Analyst Ratings
Consensus ($5.75 target)
1
Strong Buy6
BuyData last updated: 4/8/2026